Asset profile
exendin-4 Fc fusion (JY09)
Protein / enzyme therapeutic
Evidence outlook · lead readout
NCT06247748 · Diabetes Mellitus, Type 2, Overweight
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT06247748: Every participant received the same open-label treatment with no control group, and the study measured drug-interaction and pharmacokinetic markers rather than a clinical benefit. No results have been posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.